Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 421 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and... October 20, 2022 The Nobel Prize in Chemistry 2020 was Awarded “for the Development... October 12, 2020 Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... February 10, 2025 EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel May 27, 2022 Load more HOT NEWS Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours Tratamiento agnóstico contra el cáncer: perspectiva de un experto ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,...
